Current Developments in Cyclophosphamide for Lymphoma: Immunomodulation, Metronomic Approaches, and Toxicity Control

Authors

  • A. Mohamed Sikkander* Department of Chemistry, Velammal Engineering College, Chennai-600066 INDIA Author
  • C. Hazarathaiah Yadav Department of Chemistry, Vel Tech Rangarajan Dr. Sakunthala R & D Institute of science & Technology, Avadi, Chennai, India. Author
  • Narendra Revanuri Department of Chemistry, Vel Tech Rangarajan Dr. Sakunthala R & D Institute of science & Technology, Avadi, Chennai, India. Author

Keywords:

haematopoietic cells, polatuzumab, bendamustine, rituximab, lenalidomide, antimitotic, antineoplastic products.

Abstract

Cyclophosphamide is a medication that is mostly used to treat tumours, including multiple myeloma, cancer, and bone cancer.  Nitrogen mustard, or cyclophosphamide, has anti-neoplastic properties through end-to-end alkylation.  An interdisciplinary collaboration examines the recommendations, contraindications, mode of action, and other important aspects of cyclophosphamide as a valuable agent in the therapy and management of neoplastic diseases.  The use of cyclophosphamide in the treatment of severe multiple sclerosis is also discussed.  Determine the cyclophosphamide's mode of action and administration.  Describe cyclophosphamide's side effects and contraindications. Examine the relevant cyclophosphamide toxin and monitoring. In order to improve cyclophosphamide and alleviate problems, summarise interprofessional platoon techniques for improving care collaboration and communication. One kind of nitrogen mustard medication that works by alkylating DNA is cyclophosphamide.  The medication metabolises into an active form that can prevent protein conflation through DNA and RNA crosslinking, and it is not cell-cycle phase-specific.  The phosphoramide mustard produced by the drug's metabolism by liver enzymes such cytochrome P-450 is responsible for the maturity of cyclophosphamide's antineoplastic products.  Cyclophosphamide is initially converted by hepatic enzymes to hydroxycyclophosphamide, which is subsequently metabolised to aldophosphamide.  Phosphoramide mustard and acrolein, the primary alkylating agent, bind to aldophosphamide. At the guanine N-7 site, the phosphoramide metabolite creates cross-links both within and between conterminous DNA strands.The result of these infinite variations is programmed cell death.  Although acrolein has no anticancer activity, it is the primary cause of hemorrhagic cystitis. Cyclophosphamide possesses immunosuppressive properties and T cell selectivity in addition to its antimitotic and antineoplastic properties.

 

References

1. Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, Ragnaud JM, Leng B, Moreau JF. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999 Jan;115(1):189-95. doi: 10.1046/j.1365-2249.1999.00766.x.

2. Lugtenburg PJ, Mutsaers PGNJ. How I treat Elderly Patients with DLBCL in the frontline setting. Blood. 2022 Nov 22:blood.2020008239. doi: 10.1182/blood.2020008239.

3. Abbasi M, Rolfson D, Khera AS, Dabravolskaj J, Dent E, Xia L. Identification and management of frailty in the primary care setting. CMAJ. 2018 Sep 24;190(38):E1134-E1140. doi: 10.1503/cmaj.171509.

4. Bajracharya R, Song JG, Patil BR, Lee SH, Noh HM, Kim DH, Kim GL, Seo SH, Park JW, Jeong SH, Lee CH, Han HK. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv. 2022 Dec;29(1):1959-1970. doi: 10.1080/10717544.2022.2089296.

5. Nagler A, Labopin M, Arat M, Reményi P, Koc Y, Blaise D, Angelucci E, Vydra J, Kulagin A, Socié G, Rovira M, Sica S, Aljurf M, Gülbas Z, Kröger N, Brissot E, Peric Z, Giebel S, Ciceri F, Mohty M. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT. Cancer. 2022 Nov 15;128(22):3959-3968. doi: 10.1002/cncr.34452.

6. Nuzzo, G.; Senese, G.; Gallo, C.; Albiani, F.; Romano, L.; d’Ippolito, G.; Manzo, E.; Fontana, A. Antitumor Potential of Immunomodulatory Natural Products. Mar. Drugs 2022, 20, 386. https://doi.org/10.3390/md20060386

7. Yunis J, Short KR, Yu D. Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. Trends Microbiol. 2023 Jan 10:S0966-842X (22)00342-0. doi: 10.1016/j.tim.2022.12.008. Epub ahead of print. PMID: 36635162; PMCID: PMC9829516.

8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100A.) CYCLOPHOSPHAMIDE. https://www.ncbi.nlm.nih.gov/books/NBK304336/

9. Miriyala LKV, Avasthi D. Cutaneous Multiple Myeloma. Cureus. 2021 Sep 6;13(9):e17779. doi: 10.7759/cureus.17779.

10. Cucer F, Miron I, Müller R, Iliescu Halitchi C, Mihaila D. Treatment with Cyclophosphamide for steroid-resistant nephrotic syndrome in children. Maedica (Bucur). 2010 Jul;5(3):167-70.

11. Tapia C, Bashir K. Nephrotic Syndrome. [Updated 2022 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2023Jan. https://www.ncbi.nlm.nih.gov/books/NBK470444/

12. https://www.childrensmn.org/educationmaterials/childrensmn/article/15662/cyclophosphamide-cytoxan/

13. https://www.webmd.com/drugs/2/drug-6093/cyclophosphamide-oral/details

14. https://www.mayoclinic.org/drugs-supplements/cyclophosphamide-oral-route-intravenous-route/precautions/drg-20063307?p=1

15. https://www.mayoclinic.org/drugs-supplements/cyclophosphamide-oral-route-intravenous-route/proper-use/drg-20063307

16. https://www.oncolink.org/cancer-treatment/oncolink-rx/cyclophosphamide-oral-formulation-cytoxan-r-neosar-r-endoxan-r

17. Sikkander, A. M. (2022). Duct cancer evaluation in situ–review. In Acta Biology Forum (pp. 01-04).

18. Sikkander, M., Vedhi, C., & Manisankar, P. (2012). Cyclic voltammetric determination of 1, 4-Dihydro pyridine drugs using MWCNTs modified glassy carbon electrode. Der Chem. Sin, 3, 413-420.

19. A. Mohamed Sikkander (2022). Intrathecal Chemotherapy for Blood Cancer Treatment. Acta Biology Forum.V01i01, 14-17. DOI: https://doi.org/10.5281/zenodo.7008901

20. Sikkander, M., & Nasri, N. S. (2013). Review on Inorganic Nano crystals unique benchmark of Nanotechnology. Moroccan Journal of Chemistry, 1(2), J-Chem.

21. Yadav, C. H., Revanuri, N., & Sikkander, A. R. M. (2025). Tungsten-based compounds: A new frontier in cancer diagnosis and therapy. Journal of Applied Organometallic Chemistry, 5, 149-167.

22. Sikkander, A. R. M. (2025). RUTHENIUM ORGANOMETALLIC COMPOUNDS IN CANCER TREATMENT. Biomedical Engineering: Applications, Basis and Communications, 37(01), 2430003.

23. Yadav,H,C., Revanuri,N., Sikkander,A.R.M, 2025. Organometallic Compounds phototoxicityagaint cancer cells. Biomedical Engineering Applications Basis and Communications, 2550020. http://dx.doi.org/10.4015/S1016237225500206

24. Sikkander, A. R. M., Meena, M., Yadav, H., Wahi, N., & Lakshmi, V. V. (2024). Appraisal of the impact of applying organometallic compounds in cancer therapy. Journal of Applied Organometallic Chemistry, 4, 145-166.

Downloads

Published

2025-11-21

Issue

Section

Articles

How to Cite

[1]
A. Mohamed Sikkander*, C. Hazarathaiah Yadav, and Narendra Revanuri, Trans., “Current Developments in Cyclophosphamide for Lymphoma: Immunomodulation, Metronomic Approaches, and Toxicity Control”, WJAMS, vol. 2, no. 11, pp. 4–6, Nov. 2025, Accessed: Feb. 05, 2026. [Online]. Available: https://wasrpublication.com/index.php/wjams/article/view/177

Similar Articles

You may also start an advanced similarity search for this article.